I assume this was made based upon NICE having given identical approvals for the currently recommended GLP-1 RAs, all of which are at odds with international guidelines such as the ADA/EASD Consensus Report
In other words, BPC 157 may support the conditions that allow hypertrophy training to continue, but it should not be framed as a direct muscle-growth peptide
One patient was presumed to have developed pancreatitis secondary to GLP1RA semaglutide due to close temporal correlation with the start of the medication and the agent was discontinued
However, as an antioxidant, it can improve overall health which may indirectly influence mood
Its standout feature lies in being a non-injectable GLP-1 receptor agonist, simplifying treatment without the need for complex machinery
Kumarathurai P, Sajadieh A, Anholm C, Kristiansen OP, Haugaard SB, Nielsen OW